Human medicines European public assessment report (EPAR): Alkindi, hydrocortisone, Date of authorisation: 09/02/2018, Revision: 13, Status: Authorised

Declaration of interests: Silvy da Rocha Dias

Declaration of interests: Virginia Rojo Guerra

Opinion/decision on a Paediatric investigation plan (PIP): Fintepla, fenfluramine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0390/2022

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000229605

Highlight report - Combination Products Operational Group (COMBO) - In Vitro Diagnostics stream - June 2026

Organisation chart: Information Management

EMA/PE/0000235658

EMA/PE/0000240018

Opinion/decision on a Paediatric investigation plan (PIP): Jyseleca, filgotinib maleate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: EMA/PE/0000232302